Digoxin · Lanoxicaps, Lanoxin

What is Digoxin?

Digoxin is a cardiac glycoside that inhibits Na-K ATPase, increasing intracellular calcium in the myocardium and enhancing cardiac contractility. It slows heart rate and reduces conduction velocity through the atrioventricular node.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Lanoxicaps, Lanoxin

Drug type

Small molecule

Targets

Na-K ATPase (ATP1A1)

Mechanism

Inhibitor of Na-K ATPase (ATP1A1)

Pathways

cardiac contractility, autonomic nervous system, renin-angiotensin system

Therapy area

Cardiovascular

Developer

Azurity

In trials of

LXRX

FDA status

Approved as Lanoxicaps, Lanoxin (November 16, 1954), NDA009330 · FDA label

✅ FDA-approved uses

• Mild to moderate heart failure in adults (Lanoxin)
• Heart failure in pediatric patients (Lanoxin)
• Chronic atrial fibrillation in adults (Lanoxin)
• Mild to moderate heart failure in adults (Digoxin)
• Heart failure in pediatric patients (Digoxin)
• Chronic atrial fibrillation in adults (Digoxin)

From the indications section of the FDA label (version of Oct 17, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Sources

• FDA label (DailyMed)
• FDA label Lanoxin (2025-10-17), indications
• FDA label Digoxin (2025-04-10), indications
• ClinicalTrials.gov NCT02300350

Updated Oct 3, 2026.